Clinical endocrinology
-
Clinical endocrinology · Jan 2005
Randomized Controlled Trial Clinical TrialRosiglitazone improves insulin sensitivity and glucose tolerance in subjects with impaired glucose tolerance.
This study was designed to evaluate the effects of rosiglitazone (ROS) on insulin sensitivity, beta-cell function, and glycaemic response to glucose challenge and meal in subjects with impaired glucose tolerance (IGT). ⋯ Rosiglitazone treatment significantly improved insulin resistance and reduced postchallenge glucose and insulin concentrations in patients with impaired glucose tolerance without remarkable effects on beta-cell secretory function.